Literature DB >> 28993275

The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.

Kai Wang1, Tiansheng Shen1, Gene P Siegal1, Shi Wei2.   

Abstract

Compelling evidence has demonstrated the prognostic value of tumor-infiltrating lymphocytes (TILs), especially in triple-negative breast cancer (TNBC). However, only a limited number of studies to investigate the importance of the subsets of T cells in TILs have been carried out, less so the significance of the location of these TILs. In this study, we explored in a cohort of 42 consecutive TNBC cases the prognostic significance of TIL subsets at the tumor-host interface (within 1 high-power field [0.5 mm] of the invasive front) and compared them with TILs within the intratumoral stroma. Given the reported importance of TILs in HER2-overexpressing breast cancer, a subset of such tumors was also included for comparison. The range was wide in both locations; nevertheless, the mean CD4+ and CD8+ T cell count was significantly higher at the tumor-host interface than that found within the intratumoral stroma (both P<.0001). The number of CD4+ or CD8+ T cells at either location was not significantly associated with distant relapse-free or overall survival. However, the CD4/CD8 ratio at the tumor-host interface was significantly associated with both relapse-free survival (hazard ratio 0.2, P=.002) and overall survival (hazard ratio 0.13, P=.002), whereas this association was not seen for the CD4/CD8 ratio within the intratumoral stroma. As expected, both tumor size and nodal status were significantly associated with survival outcomes. The findings further support the contention that TILs, as markers of regional immune escape, are of prognostic importance in TNBC progression and that the CD4/CD8 ratio of TILs at the tumor-host interface plays a distinctive role, thus appearing to be of clinical relevance.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; CD4; CD8; Triple negative; Tumor-infiltrating lymphocytes

Mesh:

Year:  2017        PMID: 28993275     DOI: 10.1016/j.humpath.2017.09.012

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  32 in total

1.  A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer.

Authors:  Rachel L Stewart; Katherine L Updike; Rachel E Factor; N Lynn Henry; Kenneth M Boucher; Philip S Bernard; Katherine E Varley
Journal:  Cancer Res       Date:  2019-05-02       Impact factor: 12.701

2.  Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies.

Authors:  Tanmoy Mondal; Gururaj N Shivange; Rachisan Gt Tihagam; Evan Lyerly; Michael Battista; Divpriya Talwar; Roxanna Mosavian; Karol Urbanek; Narmeen S Rashid; J Chuck Harrell; Paula D Bos; Edward B Stelow; M Sharon Stack; Sanchita Bhatnagar; Jogender Tushir-Singh
Journal:  EMBO Mol Med       Date:  2021-02-15       Impact factor: 12.137

3.  Effects of ultrasound-guided erector spinae plane block on the immune function and postoperative recovery of patients undergoing radical mastectomy.

Authors:  Yunxia Hu; Meiting Li; Jiacen Li; Qiang Lyu; Rong Jiang; Yu Du
Journal:  Gland Surg       Date:  2021-10

4.  Prognostic Relevance of Pretreatment Peripheral Neutrophil Count and Neutrophil-to-lymphocyte Ratio in Primary Cutaneous Angiosarcoma.

Authors:  Kentaro Awaji; Takuya Miyagawa; Jun Omatsu; Hiroko Numajiri; Toru Kawai; Kaoru Funamizu; Ryosuke Saigusa; Daisuke Yamada; Yoshihide Asano; Shinichi Sato
Journal:  Acta Derm Venereol       Date:  2021-08-25       Impact factor: 3.875

5.  Exercise Training Improves Tumor Control by Increasing CD8+ T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade.

Authors:  Igor L Gomes-Santos; Zohreh Amoozgar; Ashwin S Kumar; William W Ho; Kangsan Roh; Nilesh P Talele; Hannah Curtis; Kosuke Kawaguchi; Rakesh K Jain; Dai Fukumura
Journal:  Cancer Immunol Res       Date:  2021-04-10       Impact factor: 11.151

6.  B-cell populations are expanded in breast cancer patients compared with healthy controls.

Authors:  Banri Tsuda; Asuka Miyamoto; Kozue Yokoyama; Rin Ogiya; Risa Oshitanai; Mayako Terao; Toru Morioka; Naoki Niikura; Takuho Okamura; Hirohito Miyako; Yuki Saito; Yasuhiro Suzuki; Yoshie Kametani; Yutaka Tokuda
Journal:  Breast Cancer       Date:  2017-12-04       Impact factor: 4.239

7.  Tumor-Infiltrating CD8 T Cells Predict Clinical Breast Cancer Outcomes in Young Women.

Authors:  Yong Won Jin; Pingzhao Hu
Journal:  Cancers (Basel)       Date:  2020-04-26       Impact factor: 6.639

8.  Clinicopathologic Characteristics of Breast Cancer According to the Infiltrating Immune Cell Subtypes.

Authors:  Hye Min Kim; Ja Seung Koo
Journal:  Int J Mol Sci       Date:  2020-06-22       Impact factor: 5.923

9.  Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.

Authors:  Nanna Jørgensen; Thomas Vauvert F Hviid; Lise B Nielsen; Ida M H Sønderstrup; Jens Ole Eriksen; Bent Ejlertsen; Anne-Marie Gerdes; Torben A Kruse; Mads Thomassen; Maj-Britt Jensen; Anne-Vibeke Lænkholm
Journal:  Br J Cancer       Date:  2021-08-07       Impact factor: 9.075

Review 10.  Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy.

Authors:  Michael F Coleman; Alyssa J Cozzo; Alexander J Pfeil; Suhas K Etigunta; Stephen D Hursting
Journal:  Cancers (Basel)       Date:  2020-04-01       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.